187 related articles for article (PubMed ID: 12586776)
1. Contrasting effects of prenyltransferase inhibitors on estrogen-dependent cell cycle progression and estrogen receptor-mediated transcriptional activity in MCF-7 cells.
Doisneau-Sixou SF; Cestac P; Chouini S; Carroll JS; Hamilton AD; Sebti SM; Poirot M; Balaguer P; Faye JC; Sutherland RL; Favre G
Endocrinology; 2003 Mar; 144(3):989-98. PubMed ID: 12586776
[TBL] [Abstract][Full Text] [Related]
2. Prenylation inhibitors stimulate both estrogen receptor alpha transcriptional activity through AF-1 and AF-2 and estrogen receptor beta transcriptional activity.
Cestac P; Sarrabayrouse G; Médale-Giamarchi C; Rochaix P; Balaguer P; Favre G; Faye JC; Doisneau-Sixou S
Breast Cancer Res; 2005; 7(1):R60-70. PubMed ID: 15642170
[TBL] [Abstract][Full Text] [Related]
3. Differential recruitment of coregulator proteins steroid receptor coactivator-1 and silencing mediator for retinoid and thyroid receptors to the estrogen receptor-estrogen response element by beta-estradiol and 4-hydroxytamoxifen in human breast cancer.
Fleming FJ; Hill AD; McDermott EW; O'Higgins NJ; Young LS
J Clin Endocrinol Metab; 2004 Jan; 89(1):375-83. PubMed ID: 14715875
[TBL] [Abstract][Full Text] [Related]
4. A fusion protein of the estrogen receptor (ER) and nuclear receptor corepressor (NCoR) strongly inhibits estrogen-dependent responses in breast cancer cells.
Chien PY; Ito M; Park Y; Tagami T; Gehm BD; Jameson JL
Mol Endocrinol; 1999 Dec; 13(12):2122-36. PubMed ID: 10598586
[TBL] [Abstract][Full Text] [Related]
5. Relationship between expression of coactivators and corepressors of hormone receptors and resistance of ovarian cancers to growth regulation by steroid hormones.
Havrilesky LJ; McMahon CP; Lobenhofer EK; Whitaker R; Marks JR; Berchuck A
J Soc Gynecol Investig; 2001; 8(2):104-13. PubMed ID: 11336882
[TBL] [Abstract][Full Text] [Related]
6. Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts.
Sun J; Qian Y; Hamilton AD; Sebti SM
Oncogene; 1998 Mar; 16(11):1467-73. PubMed ID: 9525745
[TBL] [Abstract][Full Text] [Related]
7. Involvement of G1/S cyclins in estrogen-independent proliferation of estrogen receptor-positive breast cancer cells.
Bindels EM; Lallemand F; Balkenende A; Verwoerd D; Michalides R
Oncogene; 2002 Nov; 21(53):8158-65. PubMed ID: 12444551
[TBL] [Abstract][Full Text] [Related]
8. Transcriptional regulation of vascular endothelial growth factor by estradiol and tamoxifen in breast cancer cells: a complex interplay between estrogen receptors alpha and beta.
Buteau-Lozano H; Ancelin M; Lardeux B; Milanini J; Perrot-Applanat M
Cancer Res; 2002 Sep; 62(17):4977-84. PubMed ID: 12208749
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines.
Lerner EC; Zhang TT; Knowles DB; Qian Y; Hamilton AD; Sebti SM
Oncogene; 1997 Sep; 15(11):1283-8. PubMed ID: 9315095
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of estrogen receptor alpha expression and function in MCF-7 cells by kaempferol.
Hung H
J Cell Physiol; 2004 Feb; 198(2):197-208. PubMed ID: 14603522
[TBL] [Abstract][Full Text] [Related]
11. Estrogen receptor expression and function in long-term estrogen-deprived human breast cancer cells.
Jeng MH; Shupnik MA; Bender TP; Westin EH; Bandyopadhyay D; Kumar R; Masamura S; Santen RJ
Endocrinology; 1998 Oct; 139(10):4164-74. PubMed ID: 9751496
[TBL] [Abstract][Full Text] [Related]
12. Differential effects of estradiol and its analogs on cyclin D1 and CDK4 expression in estrogen receptor positive MCF-7 and estrogen receptor-transfected MCF-10AEwt5 cells.
Hong J; Shah NN; Thomas TJ; Gallo MA; Yurkow EJ; Thomas T
Oncol Rep; 1998; 5(5):1025-33. PubMed ID: 9683804
[TBL] [Abstract][Full Text] [Related]
13. Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells.
Yang X; Phillips DL; Ferguson AT; Nelson WG; Herman JG; Davidson NE
Cancer Res; 2001 Oct; 61(19):7025-9. PubMed ID: 11585728
[TBL] [Abstract][Full Text] [Related]
14. 4-hydroxytamoxifen trans-represses nuclear factor-kappa B activity in human osteoblastic U2-OS cells through estrogen receptor (ER)alpha, and not through ER beta.
Quaedackers ME; Van Den Brink CE; Wissink S; Schreurs RH; Gustafsson JA; Van Der Saag PT; Van Der Burg BB
Endocrinology; 2001 Mar; 142(3):1156-66. PubMed ID: 11181531
[TBL] [Abstract][Full Text] [Related]
15. Anti-estrogenic actions of histone deacetylase inhibitors in MCF-7 breast cancer cells.
De los Santos M; Martínez-Iglesias O; Aranda A
Endocr Relat Cancer; 2007 Dec; 14(4):1021-8. PubMed ID: 18045953
[TBL] [Abstract][Full Text] [Related]
16. Modulation by phenylacetate of early estrogen-mediated events in MCF-7 breast cancer cells.
Liu J; Li J; Sidell N
Cancer Chemother Pharmacol; 2007 Feb; 59(2):217-25. PubMed ID: 16738884
[TBL] [Abstract][Full Text] [Related]
17. 1alpha,25-Dihydroxyvitamin D3 down-regulates estrogen receptor abundance and suppresses estrogen actions in MCF-7 human breast cancer cells.
Swami S; Krishnan AV; Feldman D
Clin Cancer Res; 2000 Aug; 6(8):3371-9. PubMed ID: 10955825
[TBL] [Abstract][Full Text] [Related]
18. Estrogens and progesterone promote persistent CCND1 gene activation during G1 by inducing transcriptional derepression via c-Jun/c-Fos/estrogen receptor (progesterone receptor) complex assembly to a distal regulatory element and recruitment of cyclin D1 to its own gene promoter.
Cicatiello L; Addeo R; Sasso A; Altucci L; Petrizzi VB; Borgo R; Cancemi M; Caporali S; Caristi S; Scafoglio C; Teti D; Bresciani F; Perillo B; Weisz A
Mol Cell Biol; 2004 Aug; 24(16):7260-74. PubMed ID: 15282324
[TBL] [Abstract][Full Text] [Related]
19. Tamoxifen-resistant fibroblast growth factor-transfected MCF-7 cells are cross-resistant in vivo to the antiestrogen ICI 182,780 and two aromatase inhibitors.
McLeskey SW; Zhang L; El-Ashry D; Trock BJ; Lopez CA; Kharbanda S; Tobias CA; Lorant LA; Hannum RS; Dickson RB; Kern FG
Clin Cancer Res; 1998 Mar; 4(3):697-711. PubMed ID: 9533540
[TBL] [Abstract][Full Text] [Related]
20. Stromal cell-derived factor 1, a novel target of estrogen receptor action, mediates the mitogenic effects of estradiol in ovarian and breast cancer cells.
Hall JM; Korach KS
Mol Endocrinol; 2003 May; 17(5):792-803. PubMed ID: 12586845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
